TransMedics Group (TMDX) 46th Annual William Blair Growth Stock Conference summary

Key innovations and market impact

• Developed a portable, physiologic organ care system (OCS) that preserves and enhances organ viability, enabling real-time assessment and treatment during transport.

• Expanded from heart, lung, and liver to a next-generation kidney platform, targeting the largest transplant market segment.

• Created a national service network (NOP) with 19 hubs, 22 dedicated aircraft, and 140 pilots, vertically integrating logistics to ensure equitable access and maximize organ utilization.

• Proprietary digital ecosystem enables transparency, scalability, and efficient coordination among clinical stakeholders.

• Achieved the highest reported organ utilization rates globally, with 26% of U.S. transplant volume managed through their network last year and up to 98% utilization for liver, heart, and lung transplants.

Industry overview and challenges

• Organ transplantation is the gold standard for treating end-stage organ failure, offering the best patient outcomes and cost-effectiveness.

• Cold storage of donor organs leads to significant ischemic injury, limiting organ utilization and increasing post-transplant complications.

• Ischemic reperfusion injury affects up to 50% of transplants, impacting both short- and long-term outcomes and increasing costs.

• Only 63-64% of available donor organs are utilized in the U.S., with even lower rates for lungs and hearts.

• OCS technology minimizes ischemic damage through portable, oxygenated blood-based perfusion and enables ex-vivo organ optimization.

Growth strategy and future outlook

• Set targets to reach 10,000 U.S. transplants by 2028, 20,000 by 2030, and 30,000 global transplants by 2032, driven by kidney platform launch and international expansion.

• 2026–2027 will be investment-heavy, focusing on Gen 2 technology for heart and lung, and launching the kidney platform in 2027.

• Plans to introduce remotely monitored, cloud-based OCS Gen 3 for scalable, efficient operations.

• International expansion, especially in Europe, is a key long-term growth driver, with European partners seeking to replicate the U.S. NOP model.

• Plans include next-generation OCS devices, clinical trials for OCS Kidney, and expansion of international programs through 2029 and beyond.